The share of biosimilars in daily therapy doses continued to rise last year. For substances for which biosimilars are available, the average share of biosimilars in Germany increased to 66.3%. The use of biosimilars saved around EUR 1.5 billion in 2021.

Further figures, data and analyses can be found here: